Zobrazeno 1 - 10
of 38
pro vyhledávání: '"David R. Knop"'
Autor:
Guo-jie Ye, Chunjuan Song, Judith A Newmark, Artur V. Cideciyan, Paulette M. Robinson, William A. Beltran, Adrian M. Timmers, David R. Knop, Jeffrey D. Chulay, Valerie L. Dufour, Mark S. Shearman, Malgorzata Swider, Samuel G. Jacobson, Gustavo D. Aguirre
Publikováno v:
Human Gene Therapy. 31:743-755
Recombinant adeno-associated viral (rAAV) vector-mediated gene therapy is being developed to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retinitis pigmentosa GTPase...
Autor:
Savitri Mandapati, Chunjuan Song, Alok K. Sharma, Mailin Van Hoosear, William W. Hauswirth, Guo-jie Ye, Jeffrey D. Chulay, Adrian M. Timmers, Cayrn Plummer, Ping Zhu, David R. Knop, Kari B. Green, Paulette M. Robinson, Peter Sonnentag, Wen-Tao Deng, Mark S. Shearman, Thomas J. Conlon, Kirsten E. Coleman
Publikováno v:
Human Gene Therapy Clinical Development. 29:188-197
Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated AAV2tYF-GRK1-RPGRco, to treat retinitis pigmentosa (RP) in patients with mutations in the retinitis pigmentosa
Autor:
Chunjuan, Song, Valérie L, Dufour, Artur V, Cideciyan, Guo-Jie, Ye, Malgorzata, Swider, Judith A, Newmark, Adrian M, Timmers, Paulette M, Robinson, David R, Knop, Jeffrey D, Chulay, Samuel G, Jacobson, Gustavo D, Aguirre, William A, Beltran, Mark S, Shearman
Publikováno v:
Hum Gene Ther
Recombinant adeno-associated viral (rAAV) vector-mediated gene therapy is being developed to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. In preparation for a clinical
Autor:
Chunjuan Song, Mark S. Shearman, Guo-jie Ye, Artur V. Cideciyan, Paulette M. Robinson, Gui-Shuang Ying, Gustavo D. Aguirre, Valerie L. Dufour, Malgorzata Swider, Adrian M. Timmers, William A. Beltran, Nicole M. Weinstein, Perry L. Habecker, Wei Pan, David R. Knop, Samuel G. Jacobson, Jeffrey D. Chulay, Amy C. Durham
Publikováno v:
Hum Gene Ther
Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated rAAV2tYF-GRK1-hRPGRco, to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retiniti
Autor:
Chantelle Gaskin, Tanaz Farivar, Heikki T Turunen, David R. Knop, Chunjuan Song, Judith A Newmark, Mark S. Shearman, Steven Pennock, Guo-jie Ye, Adrian M. Timmers, Jilin Liu
Publikováno v:
Human gene therapy. 31(1-2)
Both subretinal dosing and intravitreal (IVT) dosing of adeno-associated virus (AAV) in higher species induce mild and transient inflammatory responses that increase with dose. Foreign protein and foreign DNA are known inducers of inflammation, which
Autor:
Kirsten E. Erger, Alok K. Sharma, Thomas J. Conlon, Jeffrey D. Chulay, Guo-jie Ye, David R. Knop, Peter Sonnentag, Kellie Howard
Publikováno v:
Human Gene Therapy Clinical Development. 26:177-184
Applied Genetic Technologies Corporation is developing a recombinant adeno-associated virus (rAAV) vector for treatment of X-linked retinoschisis (XLRS), an inherited retinal disease characterized by splitting (schisis) of the layers of the retina, w
Autor:
Jonathan Stoddard, Martha Neuringer, Kellie Howard, James N. Ver Hoeve, Jeffrey D. Chulay, Alok K. Sharma, Ewa Budzynski, Peter Sonnentag, Guo-jie Ye, David R. Knop, Trevor J. McGill, Paul E. Miller
Publikováno v:
Human Gene Therapy Clinical Development. 26:165-176
Applied Genetic Technologies Corporation is developing rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus (rAAV) vector for treatment of X-linked retinoschisis (XLRS), an inherited retinal disease characterized by splitting (schisis) of retinal l
Autor:
Elisha Gootwine, Ron Ofri, Eyal Banin, Raaya Ezra-Elia, Alexey Obolensky, David R. Knop, Alexander Rosov, Mark S. Shearman, Paulette M. Robinson, Esther Yamin, Jeffrey D. Chulay, Edward Averbukh, Maya Ross, Hen Honig, Guo-jie Ye
Publikováno v:
Human gene therapy. Clinical development. 28(2)
Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector expressing the human CNGA3 gene designated AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) for the treatment of achromatopsia, an inherited retinal diso
Autor:
Roberto Calcedo, Paul E. Miller, Jeffrey D. Chulay, James N. Ver Hoeve, David R. Knop, Ewa Budzynski, Guo-jie Ye, Alok K. Sharma, Leia M. Smith, Paulette M. Robinson, William W. Hauswirth, Chantelle Gaskin, Peter Sonnentag, T Michael Nork, Tara Arndt
Publikováno v:
Human Gene Therapy Clinical Development.
Applied Genetic Technologies Corporation (AGTC) is developing rAAV2tYF-PR1.7-hCNGB3, a recombinant adeno-associated viral (rAAV) vector expressing the human CNGB3 gene, for treatment of achromatopsia, an inherited retinal disorder characterized by ma
Autor:
Peter Sonnentag, William W. Hauswirth, James N. Ver Hoeve, Savitri Mandapati, Roberto Calcedo, Ewa Budzynski, Leslie E McPherson, Jeffrey D. Chulay, David R. Knop, Paulette M. Robinson, Tara Arndt, Guo-jie Ye, Leia M. Smith, T Michael Nork, Paul E. Miller
Publikováno v:
Human Gene Therapy Clinical Development.
Applied Genetic Technologies Corporation (AGTC) is developing rAAV2tYF-PR1.7-hCNGB3, a recombinant adeno-associated virus (rAAV) vector expressing the human CNGB3 gene, for treatment of achromatopsia, an inherited retinal disorder characterized by ma